Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
larger decrease » marked decrease (Expand Search)
teer decrease » mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
521
-
522
-
523
-
524
-
525
-
526
-
527
SDI-based age-standardized rates of DALYs and ASDR for IHD attributable to HSBP.
Published 2025Subjects: -
528
-
529
Magnetic Fields Generated by Directed Ionic Flow
Published 2024“…Our experimental results reveal that the magnetic flux density is directly proportional to the current intensity and decreases with larger distances. Furthermore, it increases with the number of effective coils and decreases with larger conduit sizes, demonstrating the significant impact of conduit shape on the generated magnetic field. …”
-
530
Magnetic Fields Generated by Directed Ionic Flow
Published 2024“…Our experimental results reveal that the magnetic flux density is directly proportional to the current intensity and decreases with larger distances. Furthermore, it increases with the number of effective coils and decreases with larger conduit sizes, demonstrating the significant impact of conduit shape on the generated magnetic field. …”
-
531
Data Sheet 1_Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greate...
Published 2025“…Background<p>Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. …”
-
532
Study selection criteria.
Published 2025“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”
-
533
PICOS criteria for the SLR.
Published 2025“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”
-
534
PRISMA flow chart.
Published 2025“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”
-
535
-
536
Flowchart of the study.
Published 2024“…At species level, <i>Schaalia</i> spp., <i>Streptococcus gordonii</i>, and <i>Leptotrichia wadei</i> increased in Placebo and decreased in the Probiotic group after treatment. <i>Granulicatella adiacens</i> decreased significantly after the probiotic therapy, while <i>Saccharibacteria</i> (TM7) spp., <i>Solobacterium moorei</i>, and <i>Catonella morbi</i> increased significantly. …”
-
537
Flowchart of the screening process.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
538
Result of the AMSTAR-2 assessments.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
539
Characteristics of included reviews.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”
-
540
Result of the PRISMA assessments.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”